Sends first batch of cell lines for cGMP production of Clinical grade biosimilars to Inno Biologics, Malaysia
Avesthagen Limited, a leading systems biology biotechnology company headquartered in Bangalore, India announced the commencement of the manufacture of two of its biosimilars at Inno Biologic’s Putra Nilai facilities in Malaysia.
Avesthagen has built a robust pipeline of eight Biosimilars of which four are in an advanced stage of development. The first product for anaemia, AVDESP™ has already completed preclinicals and is ready for cGMP manufacturing for conducting clinical trials in India. The second biosimilar for auto-immune disorders, AVENT™, will also be produced at the Inno Biologics facility. Inno Biologics has been contracted to produce clinical grade material of Avesthagen’s biosimilars, which will be used for human trials.
“We are very excited about working with Inno Biologics as we advance our pipeline through the regulatory process and then to commercialisation,” said Dr. Villoo Morawala Patell, Founder, Chairperson & Managing Director of Avesthagen. “We are especially pleased with the way in which Inno Biologics has shown a willingness to adapt and be flexible in responding to our needs. We are extremely satisfied and look forward to a very successful partnership,” she added “We are pleased that Avesthagen has chosen Inno Biologics as their manufacturing partner for this project from a list of other contenders across Asia. Inno Biologics will strive to uphold this trust and deliver the project with utmost dedication to quality, speed and value. The project is a reflection of our continuous effort to differentiate ourselves and to suit the customer’s ever challenging demands. Inno Biologics’ team is primed and ready to deliver, ” said Dato’ Mohd Nazlee Kamal, Group Managing Director of Inno Bio Ventures Sd. Bhd. when asked to comment.
About Avesthagen
AVESTHAGEN LIMITED is India’s leading integrated systems biology platform company that focuses on achieving convergence of food, pharma and population genetics leading to predictive preventive and personalized healthcare. It employs 400 people worldwide and is headquartered in Bangalore. Avesthagen Limited has established world class, state-of-the-art laboratory facilities in Bangalore. It began business operations in 2001. Since its inception Avesthagen has grown into one of India's, leading healthcare biotech companies in addition to its agri-biotechnologies product pipeline, development of clinically validated botanical bioActives, derived from Indian medicinal plants, as well as the development of a pipeline of bio-similar drugs.
Avesthagen Limited has four strategic business units: bioPharmaceuticals, bioNutrition, bioAgriculture and Science & Innovation. Its partners include multiple top 10 global companies in each of its fields of research. Avesthagen Limited collaborates at every stage in the value chain with appropriate partners, both public and private, for access to and exchange of technology and overall commercial expertise to leverage the ‘India advantage’.
